METHODS: Comprehensive analyses employing genetic modulation (USP1 knockdown and overexpression), pharmacological inhibition, and a series of in vitro and in vivo assays were conducted to assess the effects of USP1 on HCC cell sensitivity to Lenvatinib. This evidence concerns the gene USP1 and hepatocellular carcinoma.